Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
siRNA (PMP22-targeting, FALCON-conjugated)

DTx-1252

An investigational treatment for Charcot-Marie-Tooth Disease.

Phase 1by Novartis (acquired DTx Pharma in 2023)
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Drug facts

The same compound appears under different names depending on the context. Here is how to identify DTx-1252 wherever you encounter it, plus the key facts at a glance.

Generic name
DTx-1252
Development codes
DTx-1252, DTX-1252
Drug class
siRNA (PMP22-targeting, FALCON-conjugated)
Manufacturer
Novartis (acquired DTx Pharma in 2023)
How it's taken
The EDK060 study gives a single IV infusion.

An investigational siRNA therapy designed to lower PMP22 expression in CMT1A using DTx Pharma's FALCON conjugation platform.

  • It was originally developed by DTx Pharma and acquired by Novartis in a deal announced July 17, 2023; BioPharma Dive reported that day that the deal closed on July 14, 2023, with $500 million paid upfront and up to $500 million more tied to milestones.
  • DTx-1252 is one of several next-generation PMP22-targeted programs aimed at the most common form of CMT.
Follow DTx-1252 by email

We'll email you when the FDA acts on DTx-1252 and when new trials for Charcot-Marie-Tooth Disease open. Unsubscribe anytime.

You'll get, for Charcot-Marie-Tooth Disease:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.

We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

Where DTx-1252 fits

Investigational, not approved.

  • One of several PMP22-targeted programs in development for CMT1A, alongside other antisense and gene-therapy approaches at various stages.
  • Only relevant for patients with confirmed CMT1A (PMP22 duplication on genetic testing), so confirming subtype with a broad gene panel is essential.

How DTx-1252 works

CMT1A is caused by an extra copy of the PMP22 gene, which makes nerve cells produce too much of the PMP22 protein. The protein imbalance damages myelin, the insulation around the nerves, and over years to decades produces the foot drop, leg weakness, and hand weakness that define CMT1A.

Small interfering RNAs (siRNAs) are short, lab-made double-stranded RNA molecules designed to find and silence a specific piece of messenger RNA (mRNA) inside cells. When DTx-1252's siRNA binds the PMP22 mRNA, it triggers the cell's natural RNA-interference pathway to break that mRNA down before it can be turned into protein. The result is lower PMP22 protein levels, closer to what the cell would normally produce.

The technical challenge with siRNA therapies is getting them into the right cells. Schwann cells, which make peripheral nerve myelin, are not easy to reach with standard siRNA approaches. DTx Pharma's FALCON (Fatty Acid Ligand Conjugated OligoNucleotide) platform attaches the siRNA to a fatty acid chain that helps the molecule cross into Schwann cells more efficiently. Novartis acquired DTx Pharma in 2023 partly for access to that platform.

Clinical trial results

Novartis has not published trial details under the DTx-1252 name. A Novartis first-in-human Phase 1 study of a drug called EDK060 in adults with CMT1A (NCT07140614) began in September 2025, but Novartis has not publicly confirmed whether EDK060 is DTx-1252. CMT1A patients interested in participating should monitor ClinicalTrials.gov, the Hereditary Neuropathy Foundation, and CMT Research Foundation announcements for the next enrollment phase.

Side effects and safety

Early trial safety observations

Because DTx-1252 is in early-stage clinical development, the safety profile is still being established. As a class, siRNA-based therapies have been associated with injection-site reactions, transient flu-like symptoms after dosing, and in some products liver enzyme elevations or platelet count changes that require monitoring. Novartis has not reported any human safety data under the DTx-1252 name.

This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.

Taking DTx-1252

Novartis has not published how DTx-1252 would be given. The EDK060 study gives a single IV infusion.

Development history

DTx Pharma was a small biotech developing the FALCON oligonucleotide platform with peripheral nerve targeting as a key application. In July 2023, Novartis acquired DTx Pharma for $500 million upfront plus up to $500 million in milestone payments, primarily to access the FALCON platform and the DTx-1252 program. Novartis has not published a status update under the DTx-1252 name since then.

A separate Novartis first-in-human study of a drug called EDK060 in adults with CMT1A (NCT07140614) started in September 2025, and Novartis has not said whether EDK060 is DTx-1252.

Ask anything about DTx-1252
AI-powered answers from clinical trial databases, FDA reports, and medical literature
Start withor ask

Explore Charcot-Marie-Tooth Disease trials

Other Charcot-Marie-Tooth Disease treatments

Common questions about DTx-1252

▸What is DTx-1252?

An investigational siRNA therapy designed to lower PMP22 expression in CMT1A using DTx Pharma's FALCON conjugation platform. It was originally developed by DTx Pharma and acquired by Novartis in a deal announced July 17, 2023; BioPharma Dive reported that day that the deal closed on July 14, 2023, with $500 million paid upfront and up to $500 million more tied to milestones. DTx-1252 is one of several next-generation PMP22-targeted programs aimed at the most common form of CMT.

▸How does DTx-1252 work?

CMT1A is caused by an extra copy of the PMP22 gene, which makes nerve cells produce too much of the PMP22 protein. The protein imbalance damages myelin, the insulation around the nerves, and over years to decades produces the foot drop, leg weakness, and hand weakness that define CMT1A.

Small interfering RNAs (siRNAs) are short, lab-made double-stranded RNA molecules designed to find and silence a specific piece of messenger RNA (mRNA) inside cells. When DTx-1252's siRNA binds the PMP22 mRNA, it triggers the cell's natural RNA-interference pathway to break that mRNA down before it can be turned into protein. The result is lower PMP22 protein levels, closer to what the cell would normally produce.

The technical challenge with siRNA therapies is getting them into the right cells. Schwann cells, which make peripheral nerve myelin, are not easy to reach with standard siRNA approaches. DTx Pharma's FALCON (Fatty Acid Ligand Conjugated OligoNucleotide) platform attaches the siRNA to a fatty acid chain that helps the molecule cross into Schwann cells more efficiently. Novartis acquired DTx Pharma in 2023 partly for access to that platform.

▸What are the side effects of DTx-1252?

Because DTx-1252 is in early-stage clinical development, the safety profile is still being established. As a class, siRNA-based therapies have been associated with injection-site reactions, transient flu-like symptoms after dosing, and in some products liver enzyme elevations or platelet count changes that require monitoring. Novartis has not reported any human safety data under the DTx-1252 name.

▸How is DTx-1252 taken?

Novartis has not published how DTx-1252 would be given. The EDK060 study gives a single IV infusion.

▸Is DTx-1252 FDA approved?

DTx-1252 is currently in phase 1 clinical trials for Charcot-Marie-Tooth Disease. It has not yet received FDA approval.

▸What is DTx-1252?

DTx-1252 is an investigational siRNA therapy designed to lower PMP22 expression in CMT1A, which is caused by an extra copy of the PMP22 gene. It uses the FALCON platform, which attaches the siRNA to a fatty acid chain so it can reach Schwann cells more efficiently. Novartis acquired DTx Pharma in July 2023 for $500 million upfront plus up to $500 million in milestones, according to BioPharma Dive, partly to access that platform. [1][2]

▸Is DTx-1252 FDA approved?

No, DTx-1252 is not FDA-approved. Novartis has not said whether it has reached human trials under that name, and it is only relevant for patients with confirmed CMT1A (PMP22 duplication on genetic testing). Novartis has not published trial details under the DTx-1252 name. [1][3]

▸Is there a clinical trial for DTx-1252?

A Novartis first-in-human Phase 1 study of a drug called EDK060 in adults with CMT1A (NCT07140614) began in September 2025, but Novartis has not publicly confirmed whether EDK060 is DTx-1252. CMT1A patients interested in participating should monitor ClinicalTrials.gov, the Hereditary Neuropathy Foundation, and CMT Research Foundation announcements. [4]

▸How is DTx-1252 given and what are its side effects?

Novartis has not published how DTx-1252 would be given or at what dose. Its safety profile is not yet known; as a class, siRNA therapies have been associated with injection-site reactions, temporary flu-like symptoms after dosing, and in some products liver enzyme elevations or platelet count changes that require monitoring. [3]

Sources and references

Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.

  1. Novartis · 2023-07-17. Novartis builds on neuroscience pipeline and xRNA platform capabilities with acquisition of DTx Pharma. https://www.novartis.com/news/media-releases/novartis-builds-neuroscience-pipeline-and-xrna-platform-capabilities-acquisition-dtx-pharma
  2. BioPharma Dive · 2023-07-17. Novartis buys a preclinical biotech and its RNA drug technology. https://www.biopharmadive.com/news/novartis-dtx-pharma-acquire-sirna-neuroscience/687961/
  3. CMT Research Foundation. Gene Therapy. https://cmtrf.org/gene-therapy/
  4. ClinicalTrials.gov. A First-in-human Study of EDK060 in Adults With Charcot-Marie-Tooth Type 1A (CMT1A). https://clinicaltrials.gov/study/NCT07140614

This page is for informational purposes only and does not constitute medical advice. Drug information is sourced from public databases and peer-reviewed literature and may not reflect the most recent updates. Always discuss treatment options with your healthcare provider. Last reviewed: November 2026.

Follow DTx-1252 by email

We'll email you when the FDA acts on DTx-1252 and when new trials for Charcot-Marie-Tooth Disease open. Unsubscribe anytime.

You'll get, for Charcot-Marie-Tooth Disease:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site